Should fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis?

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 5, 2007, Pages 386-387

  Hsueh, Po Ren ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DRUG SAFETY; EDITORIAL; ENDEMIC DISEASE; HUMAN; INCIDENCE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY HEALTH CARE; RISK ASSESSMENT; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HUMANS; PNEUMONIA; TAIWAN; TUBERCULOSIS;

EID: 38049079962     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Infectious Diseases Society of Taiwan. Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan. J Microbiol Immunol Infect. 2007;40:279-83.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-72.
3. Singh A. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity. Clin Infect Dis. 2007;45:133.
4. Center for Disease Control. Statistics of communicable diseases and surveillance report in Taiwan area, 2006. Taipei (Taiwan): The Center; 2007.
5. Infectious Diseases Society of the Republic of China. Guidelines for chemotherapy of tuberculosis in Taiwan. J Microbiol Immunol Infect. 2004;37:382-4.
6. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002;34:1607-12.
7. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax. 2006;61:903-8.
8. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother. 2007;59:860-5.
9. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother. 2005;56:1058-62.
10. Ruiz-Serrano MJ, Alcalá L, Martínez L, Díaz M, Marín M, González-Abad MJ, et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother. 2000;44:2567-8.